Non-Alcoholic Fatty Liver Disease (NAFLD) is a common, yet complex, hepatic disorder that is emerging as a global health burden. It is a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Understanding its causes, diagnostic methods, and modern therapeutic approaches is vital for effective patient management.
Although the pathogenesis of NAFLD is multifactorial, insulin resistance and metabolic syndrome are considered central to its development. Other factors include genetics, diet, gut microbiota, and sedentary lifestyle. NAFLD is often associated with obesity, type 2 diabetes, and dyslipidemia.
NAFLD is often silent, discovered incidentally during routine blood tests or imaging. However, a definitive diagnosis requires a liver biopsy, the gold standard for assessing liver histology. Non-invasive diagnostic strategies, such as ultrasound, elastography, and serum biomarkers, are also used to estimate liver fat content and fibrosis.
Current therapeutic strategies for NAFLD focus on lifestyle modifications, including diet and exercise. Pharmacological interventions are reserved for patients with NASH and significant fibrosis. These include insulin sensitizers, antioxidants, and lipid-lowering agents. Emerging therapies, such as FXR agonists and GLP-1R agonists, are showing promise in clinical trials.
NAFLD is a complex disease with multifactorial causes and a broad spectrum of clinical manifestations. Early identification and intervention are crucial to prevent progression to more severe liver disease. While lifestyle modification remains the cornerstone of management, advances in pharmacological therapies offer hope for more effective treatment options in the future. As our understanding of NAFLD continues to evolve, so too must our strategies for diagnosis and treatment.
1.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Radiation therapy can promote amphiregulin, which increases growth of metastases
5.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
Essential Strategies in Hematology for Healthcare Excellence
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
5.
Lymphomatoid Papulosis: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation